OPRX logo

OPRX
OptimizeRx Corp

1,142
Mkt Cap
$135.09M
Volume
937,555.00
52W High
$22.25
52W Low
$5.54
PE Ratio
27.63
OPRX Fundamentals
Price
$6.94
Prev Close
$7.20
Open
$7.26
50D MA
$7.23
Beta
1.60
Avg. Volume
597,255.78
EPS (Annual)
$0.2701
P/B
1.05
Rev/Employee
$822,774.44
$235.66
Loading...
Loading...
News
all
press releases
Can OptimizeRx's Cash Strength Cushion Near-Term Headwinds?
OPRX's rising cash flow, DAAP adoption and expanding pharma ties boost outlook despite near-term revenue softness and cautious client spending.
Zacks·8h ago
News Placeholder
More News
News Placeholder
OPRX Trades at a Discount to Industry: How to Approach the Stock Now?
OptimizeRx trades at a steep discount to peers, but strong AI-driven growth, rising cash flow and DAAP traction look encouraging.
Zacks·4d ago
News Placeholder
Should Value Investors Buy OptimizeRx (OPRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·4d ago
News Placeholder
Myomo Appoints William J Febbo to its Board of Directors
Myomo, Inc. (NYSE American: MYO) ('Myomo' or the 'Company'), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb...
Business Wire·5d ago
News Placeholder
OptimizeRx Corp. (NASDAQ:OPRX) Sees Significant Growth in Short Interest
OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,988,505 shares...
MarketBeat·5d ago
News Placeholder
OPRX Cuts Revenue Outlook: Temporary Reset or Structural Concern?
OptimizeRx lowers 2026 revenue forecast on shifting pharma spend and managed services drag, but signals recovery ahead and stronger EBITDA expectations.
Zacks·7d ago
News Placeholder
Are Investors Undervaluing OptimizeRx (OPRX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·20d ago
News Placeholder
New Strong Buy Stocks for April 1st
ESCA, PR, MGA, OPRX and TBLA have been added to the Zacks Rank #1 (Strong Buy) List on April 1st, 2026.
Zacks·20d ago
News Placeholder
Best Value Stocks to Buy for April 1st
TBLA, OPRX and MGA made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 1st, 2026.
Zacks·20d ago
News Placeholder
OptimizeRx Corp. (NASDAQ:OPRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine analysts that are covering the stock, MarketBeat Ratings reports. One...
MarketBeat·24d ago
<
1
2
...
>

Latest OPRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.